Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 3
2006 4
2007 7
2008 6
2009 1
2010 8
2011 6
2012 2
2013 1
2014 1
2016 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
Luna B, Townsend MU. Luna B, et al. Clin Ther. 2007 Nov;29(11):2309-18. doi: 10.1016/j.clinthera.2007.11.007. Clin Ther. 2007. PMID: 18158073 Review.
BACKGROUND: Despite the availability of a growing number of potent antiretroviral agents, efforts to completely suppress viral replication in patients with HIV-1 infection are limited because of the increasing risk of resistance. Tipranavir (TPV) is the first in a class of …
BACKGROUND: Despite the availability of a growing number of potent antiretroviral agents, efforts to completely suppress viral replication i …
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naive HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team. Cooper DA, et al. PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016. PLoS One. 2016. PMID: 26730818 Free PMC article. Clinical Trial.
Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naive HIV-1-infected patients because of its potency, unique resistance profile, and high genetic barrier. ...
Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naive HIV-1-infected patients because of its poten …
Tipranavir favored in RESIST-2.
[No authors listed] [No authors listed] AIDS Patient Care STDS. 2005 Jan;19(1):59. AIDS Patient Care STDS. 2005. PMID: 15700396 Clinical Trial. No abstract available.
Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.
Elgadi MM, Piliero PJ. Elgadi MM, et al. Drugs R D. 2011 Dec 1;11(4):295-302. doi: 10.2165/11596340-000000000-00000. Drugs R D. 2011. PMID: 22007990 Free PMC article. Clinical Trial.
BACKGROUND: The POTENT trial compared the safety and efficacy of tipranavir/ritonavir (TPV/r) to darunavir/ritonavir (DRV/r), each with an optimized background regimen (OBR) in triple-class experienced HIV-1-infected patients with resistance to more than one protease inhib …
BACKGROUND: The POTENT trial compared the safety and efficacy of tipranavir/ritonavir (TPV/r) to darunavir/ritonavir (DRV/r), each wi …
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.
Naeger LK, Struble KA. Naeger LK, et al. AIDS. 2007 Jan 11;21(2):179-85. doi: 10.1097/QAD.0b013e3280119213. AIDS. 2007. PMID: 17197808 Clinical Trial.
OBJECTIVE: To assess the resistance profile of tipranavir. METHODS: Resistance analyses were performed on Boehringer Ingelheim-sponsored studies examining the safety and efficacy of tipranavir in highly treatment-experienced individuals at 24 weeks. ...Virologic res …
OBJECTIVE: To assess the resistance profile of tipranavir. METHODS: Resistance analyses were performed on Boehringer Ingelheim-sponso …
RESIST-1 results released.
[No authors listed] [No authors listed] AIDS Patient Care STDS. 2005 Jan;19(1):58-9. doi: 10.1089/apc.2005.19.58. AIDS Patient Care STDS. 2005. PMID: 15665636 Clinical Trial. No abstract available.
Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
Berhan A, Berhan Y. Berhan A, et al. PLoS One. 2013 Apr 4;8(4):e60814. doi: 10.1371/journal.pone.0060814. Print 2013. PLoS One. 2013. PMID: 23593314 Free PMC article.
Similarly, the number of patients with viral load less than 400 copies HIV RNA/ml was significantly higher in either the tipranavir-ritonavir or darunavir-ritonavir based regimen treated group (overall OR = 3.0; 95% CI, 2.15-4.11). Meta-regression showed that the viral loa …
Similarly, the number of patients with viral load less than 400 copies HIV RNA/ml was significantly higher in either the tipranavir-r …
Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers.
Kort JJ, Aslanyan S, Scherer J, Sabo JP, Kohlbrenner V, Robinson P. Kort JJ, et al. Curr HIV Res. 2011 Jun;9(4):237-46. doi: 10.2174/157016211796320306. Curr HIV Res. 2011. PMID: 21671884 Free PMC article. Clinical Trial.
This prospective, randomized, open-label trial in healthy volunteers compared the effects of tipranavir/ritonavir (TPV/r), darunavir/ ritonavir (DRV/r), and ritonavir (RTV) alone on platelet aggregation after a single dose and at steady-state concentrations. ...
This prospective, randomized, open-label trial in healthy volunteers compared the effects of tipranavir/ritonavir (TPV/r), darunavir/ …
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, López P, Clumeck N, Gerstoft J, Stavrianeas N, Moreno S, Antunes F, Neubacher D, Mayers D. Cahn P, et al. Clin Infect Dis. 2006 Nov 15;43(10):1347-56. doi: 10.1086/508352. Epub 2006 Oct 17. Clin Infect Dis. 2006. PMID: 17051504 Clinical Trial.
BACKGROUND: Tipranavir, a novel protease inhibitor, has demonstrated antiviral activity against protease inhibitor-resistant human immunodeficiency virus type 1 (HIV-1) isolates. The Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with T
BACKGROUND: Tipranavir, a novel protease inhibitor, has demonstrated antiviral activity against protease inhibitor-resistant human im …
Efficacy and safety of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents: 5 years of experience.
Salazar JC, Cahn P, Della Negra M, De Aquino MZ, Robinson PA, Jelaska A, Mikl J. Salazar JC, et al. Pediatr Infect Dis J. 2014 Apr;33(4):396-400. doi: 10.1097/INF.0000000000000038. Pediatr Infect Dis J. 2014. PMID: 23995585 Clinical Trial.
BACKGROUND: To evaluate the long-term (up to week 292) safety, efficacy and tolerability of ritonavir-boosted tipranavir in HIV-1-infected pediatric patients. Long-term follow up of patients enrolled in the randomized, open-label pediatric trial (1182.14/PACTG1051). METHOD …
BACKGROUND: To evaluate the long-term (up to week 292) safety, efficacy and tolerability of ritonavir-boosted tipranavir in HIV-1-inf …
40 results